Global expansion BioAgilytix is actively expanding facilities and capabilities across North America, Europe, and Australia, including recent growth in the Research Triangle Park, Hamburg, and Durham. This signals increased capacity for late-stage clinical testing and GMP bioanalytical services, presenting cross-region opportunity for multinational pharma partners seeking scalable BMS and LC/MS offerings.

LC/MS Portfolio The launch of a comprehensive LC/MS portfolio and multi-million-dollar investments in LC/MS platforms indicate a strengthened capability in high-sensitivity analytics, enabling more robust pharmacokinetic, biomarker, and impurity profiling across programs from preclinical to phase 3.

Regulatory-grade services BioAgilytix provides non-GLP through GMP quality control testing and has CLIA-certified, CAP-accredited diagnostics, highlighting a broad regulatory-compliant suite. This breadth can attract sponsors needing end-to-end analytical support across development and release testing, with potential for retainer-based and project-based engagement.

Leadership recognition Award-winning leadership and scientific excellence, including the Triangle Business Journal Women in Business Award for a Scientific Officer, can be leveraged in outreach to highlight stability, expertise, and a proven track record in delivering reliable bioanalytical solutions to top biotech and pharma partners.

Strategic growth signals Ongoing investments in technology, global lab footprint, and growth of GMP bioassay capabilities point to a strategic growth trajectory and willingness to collaborate on ambitious programs, suggesting an opportunity to target mid-to-large biotech and pharma companies seeking scalable, validated analytical partners for across-the-board development needs.